XOMA (NASDAQ:XOMA) Upgraded at StockNews.com

StockNews.com upgraded shares of XOMA (NASDAQ:XOMA) from a sell rating to a hold rating in a research report report published on Tuesday morning.

Separately, HC Wainwright decreased their target price on shares of XOMA from $123.00 to $104.00 and set a “buy” rating on the stock in a research note on Monday, February 3rd.

XOMA Stock Performance

NASDAQ XOMA opened at $27.06 on Tuesday. The firm’s fifty day moving average price is $26.75 and its two-hundred day moving average price is $27.96. The stock has a market cap of $318.85 million, a PE ratio of -7.78 and a beta of 0.90. XOMA has a fifty-two week low of $19.61 and a fifty-two week high of $35.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

Insider Buying and Selling

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 7.20% of the stock is currently owned by insiders.

Institutional Trading of XOMA

Institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its position in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares during the last quarter. New York State Common Retirement Fund boosted its position in XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 800 shares during the last quarter. Wells Fargo & Company MN boosted its position in XOMA by 38.0% during the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 1,183 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in XOMA during the fourth quarter valued at $206,000. Finally, Rhumbline Advisers raised its holdings in shares of XOMA by 18.1% during the fourth quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 1,699 shares during the period. Institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.